CALQUENCE (AstraZeneca Pharmaceuticals LP)
Welcome to the PulseAid listing for the CALQUENCE drug offered from AstraZeneca Pharmaceuticals LP. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | AstraZeneca Pharmaceuticals LP |
| NON-PROPRIETARY NAME: | Acalabrutinib |
| SUBSTANCE NAME: | ACALABRUTINIB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | |
| ROUTE: | ORAL |
| DOSAGE FORM: | CAPSULE, GELATIN COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2017-10-31 |
| END MARKETING DATE: | 0000-00-00 |
CALQUENCE HUMAN PRESCRIPTION DRUG Details:
| Item Description | CALQUENCE from AstraZeneca Pharmaceuticals LP |
| LABELER NAME: | AstraZeneca Pharmaceuticals LP |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 100(mg/1) |
| START MARKETING DATE: | 2017-10-31 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0310-0512_dd4835ef-e1bc-4997-a399-1ffa2556fbfe |
| PRODUCT NDC: | 0310-0512 |
| APPLICATION NUMBER: | NDA210259 |
Other ACALABRUTINIB Pharmaceutical Manufacturers / Labelers:
